Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 1
2007 1
2008 1
2009 1
2010 1
2011 1
2012 2
2013 1
2014 8
2015 3
2016 1
2017 2
2018 3
2019 5
2020 6
2021 6
2022 9
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Gillece JD, Folkerts M, Reining L, Highlander SK, Robinson K, Padam S, Martinez N, Tang A, Schmolze D, Waisman J, Sedrak M, Lee PP, Mortimer J. Yuan Y, et al. Among authors: frankel ph. Oncologist. 2021 Feb;26(2):99-e217. doi: 10.1002/onco.13583. Epub 2020 Nov 24. Oncologist. 2021. PMID: 33141975 Free PMC article. Clinical Trial.
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Yuan Y, Yost SE, Cui Y, Ruel C, Murga M, Tang A, Martinez N, Schmolze D, Waisman J, Patel N, Vora L, Tumyan L, Bozoghlanian M, Stewart D, Frankel PH. Yuan Y, et al. Among authors: frankel ph. Oncologist. 2023 Jul 5;28(7):e498-e507. doi: 10.1093/oncolo/oyad026. Oncologist. 2023. PMID: 37023705 Free PMC article. Clinical Trial.
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee PP, Waisman JR, Yuan Y. Egelston CA, et al. Among authors: frankel ph. Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027. doi: 10.1007/s00262-023-03470-y. Epub 2023 Jun 9. Cancer Immunol Immunother. 2023. PMID: 37294342 Free PMC article. Clinical Trial.
Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA.
Raoof M, Whelan RL, Sullivan KM, Ruel C, Frankel PH, Cole SE, Tinsley R, Eng M, Fakih M, Chao J, Lim D, Woo Y, Paz IB, Lew M, Cristea M, Rodriguez-Rodriguez L, Fong Y, Thomas RM, Chang S, Deperalta D, Merchea A, Dellinger TH. Raoof M, et al. Among authors: frankel ph. Ann Surg Oncol. 2023 Nov;30(12):7814-7824. doi: 10.1245/s10434-023-13941-2. Epub 2023 Jul 27. Ann Surg Oncol. 2023. PMID: 37501051 Free PMC article. Clinical Trial.
Obesity and cancer.
Frankel PH. Frankel PH. N Engl J Med. 2003 Jul 31;349(5):502-4; author reply 502-4. N Engl J Med. 2003. PMID: 12892102 No abstract available.
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Cristea MC, Stewart D, Synold T, Ruel N, Mortimer J, Wang E, Jung A, Wilczynski S, Konecny GE, Eng M, Kilpatrick L, Han E, Dellinger T, Hakim A, Lee S, Morgan RJ, Wakabayashi MT, Frankel PH. Cristea MC, et al. Among authors: frankel ph. Gynecol Oncol. 2024 Mar;182:124-131. doi: 10.1016/j.ygyno.2023.12.017. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262235 Clinical Trial.
49 results